Pfizer Inc banner

Pfizer Inc
NYSE:PFE

Watchlist Manager
Pfizer Inc Logo
Pfizer Inc
NYSE:PFE
Watchlist
Price: 27.05 USD 1.65% Market Closed
Market Cap: $153.8B

Relative Value

The Relative Value of one PFE stock under the Base Case scenario is 31.84 USD. Compared to the current market price of 27.05 USD, Pfizer Inc is Undervalued by 15%.

Relative Value is the estimated value of a stock based on various valuation multiples like P/E and EV/EBIT ratios. It offers a quick snapshot of a stock's valuation in relation to its peers and historical norms.

PFE Relative Value
Base Case
31.84 USD
Undervaluation 15%
Relative Value
Price
Worst Case
Base Case
Best Case

Multiples Across Competitors

PFE Competitors Multiples
Pfizer Inc Competitors

All Multiples
P/S
P/E
EV/EBITDA
EV/EBIT
All Countries
Close
Market Cap P/S P/E EV/EBITDA EV/EBIT
US
Pfizer Inc
NYSE:PFE
153.8B USD 2.5 19.8 7.6 10.2
US
Eli Lilly and Co
NYSE:LLY
932.9B USD 14.3 45.2 30.5 32.5
US
Johnson & Johnson
NYSE:JNJ
578.6B USD 6.1 21.6 15 18.4
CH
Roche Holding AG
SIX:ROG
271B CHF 4.4 21 12.4 13.9
CH
Novartis AG
SIX:NOVN
236.2B CHF 5.4 21.8 13.5 17.3
UK
AstraZeneca PLC
LSE:AZN
224.8B GBP 5.1 29.5 16.3 23
US
Merck & Co Inc
NYSE:MRK
287.1B USD 4.4 15.7 9.8 11.9
IE
Endo International PLC
LSE:0Y5F
218B USD 94 -74.6 344.9 865
DK
Novo Nordisk A/S
CSE:NOVO B
1.1T DKK 3.6 10.7 8 9.3
US
Bristol-Myers Squibb Co
NYSE:BMY
121B USD 2.5 17.2 7.2 8.9
UK
GSK plc
XETRA:GS71
97.2B EUR 2.6 14.8 7.5 10.7
P/E Multiple
Earnings Growth PEG
US
Pfizer Inc
NYSE:PFE
Average P/E: 21.7
19.8
22%
0.9
US
Eli Lilly and Co
NYSE:LLY
45.2
32%
1.4
US
Johnson & Johnson
NYSE:JNJ
21.6
7%
3.1
CH
Roche Holding AG
SIX:ROG
21
14%
1.5
CH
Novartis AG
SIX:NOVN
21.8
14%
1.6
UK
AstraZeneca PLC
LSE:AZN
29.5
26%
1.1
US
Merck & Co Inc
NYSE:MRK
15.7
14%
1.1
IE
E
Endo International PLC
LSE:0Y5F
Negative Multiple: -74.6 N/A N/A
DK
Novo Nordisk A/S
CSE:NOVO B
10.7
1%
10.7
US
Bristol-Myers Squibb Co
NYSE:BMY
17.2
16%
1.1
UK
GSK plc
XETRA:GS71
14.8
14%
1.1
EV/EBITDA Multiple
EBITDA Growth EV/EBITDA to Growth
US
Pfizer Inc
NYSE:PFE
Average EV/EBITDA: 43
7.6
-9%
N/A
US
Eli Lilly and Co
NYSE:LLY
30.5
22%
1.4
US
Johnson & Johnson
NYSE:JNJ
15
2%
7.5
CH
Roche Holding AG
SIX:ROG
12.4
6%
2.1
CH
Novartis AG
SIX:NOVN
13.5
5%
2.7
UK
AstraZeneca PLC
LSE:AZN
16.3
13%
1.3
US
Merck & Co Inc
NYSE:MRK
9.8
3%
3.3
IE
E
Endo International PLC
LSE:0Y5F
344.9
N/A N/A
DK
Novo Nordisk A/S
CSE:NOVO B
8
1%
8
US
Bristol-Myers Squibb Co
NYSE:BMY
7.2
-10%
N/A
UK
GSK plc
XETRA:GS71
7.5
0%
N/A
EV/EBIT Multiple
EBIT Growth EV/EBIT to Growth
US
Pfizer Inc
NYSE:PFE
Average EV/EBIT: 92.8
10.2
-4%
N/A
US
Eli Lilly and Co
NYSE:LLY
32.5
22%
1.5
US
Johnson & Johnson
NYSE:JNJ
18.4
7%
2.6
CH
Roche Holding AG
SIX:ROG
13.9
5%
2.8
CH
Novartis AG
SIX:NOVN
17.3
9%
1.9
UK
AstraZeneca PLC
LSE:AZN
23
21%
1.1
US
Merck & Co Inc
NYSE:MRK
11.9
6%
2
IE
E
Endo International PLC
LSE:0Y5F
865
N/A N/A
DK
Novo Nordisk A/S
CSE:NOVO B
9.3
3%
3.1
US
Bristol-Myers Squibb Co
NYSE:BMY
8.9
-7%
N/A
UK
GSK plc
XETRA:GS71
10.7
7%
1.5
Get AI-powered insights for any company or topic.
Open AI Assistant

Intrinsic Value is all-important and is the only logical way to evaluate the relative attractiveness of investments and businesses.

Warren Buffett